Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease

CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company… The post Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease appeared first on Ethyreal Bio .